We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has approved a new label for Novartis’ wet age-related macular degeneration (AMD) treatment Beovu (brolucizumab) with added safety information. Read More
The European Medicines Agency (EMA) said it is giving a fast-track review to a conditional marketing authorization request from Gilead Sciences for using remdesivir to treat COVID-19 patients. Read More
Recarbio was previously approved for treatment of complicated urinary tract infections and complicated intra-abdominal infections in patients with limited or no alternative treatment options. Read More